Skip to main content
Top
Published in: Clinical Rheumatology 6/2016

01-06-2016 | Original Article

Serum adropin level and ENHO gene expression in systemic sclerosis

Authors: Servet Yolbas, Murat Kara, Musa Yilmaz, Suleyman Aydin, Suleyman Serdar Koca

Published in: Clinical Rheumatology | Issue 6/2016

Login to get access

Abstract

Adropin, a secreted protein, is encoded by the energy homeostasis associated (ENHO) gene. It has been implicated in the several physiological and pathological processes such as angiogenesis and apoptosis. Therefore, the aim of present study was to investigate serum adropin levels and ENHO gene expressions in systemic sclerosis (SSc) characterized by vasculopathy, inflammation, and progressive fibrosis of the skin and internal organs. The study includes 27 patients with SSc, 39 patients with Behçet’s disease (BD), and 20 healthy controls (HC). Serum adropin levels and ENHO gene expressions by peripheral blood mononuclear cells were analyzed by ELISA method and by real-time PCR, respectively. The serum adropin levels were higher in the SSc and BD groups than in the HC group (p = 0.023 and p < 0.001, respectively). However, there were no significant differences among the groups in terms of ENHO gene expressions (p ANOVA = 0.149). There was no significant difference between the limited and diffuse cutaneous subtypes of SSc in terms of serum adropin level and ENHO gene expression. Moreover, serum adropin level and ENHO gene expression were not associated with the disease activity and severity indexes. ENHO gene expression was correlated with the triglyceride levels in the BD group (r = −0.426, p = 0.027). The augmented serum adropin levels may be expected in the chronic inflammatory disease and seem not to be characteristic of only SSc. However, further studies are needed to explain the precise role of adropin in SSc.
Literature
1.
go back to reference Ho YY, Lagares D, Tager AM, Kapoor M (2014) Fibrosis—a lethal component of systemic sclerosis. Nat Rev Rheumatol 10(7):390–402CrossRefPubMed Ho YY, Lagares D, Tager AM, Kapoor M (2014) Fibrosis—a lethal component of systemic sclerosis. Nat Rev Rheumatol 10(7):390–402CrossRefPubMed
2.
go back to reference Denton CP, Black CM (2004) Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol 18:271–290CrossRefPubMed Denton CP, Black CM (2004) Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol 18:271–290CrossRefPubMed
3.
go back to reference Trojanowska M (2010) Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6:453–460CrossRefPubMed Trojanowska M (2010) Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 6:453–460CrossRefPubMed
4.
go back to reference Kumar KG, Trevaskis JL, Lam DD et al (2008) Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8:468–481CrossRefPubMedPubMedCentral Kumar KG, Trevaskis JL, Lam DD et al (2008) Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 8:468–481CrossRefPubMedPubMedCentral
5.
go back to reference Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, Al-Omran M, Teoh H, Verma S (2010) Adropin is a novel regulator of endothelial function. Circulation 122:185–192CrossRef Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, Al-Omran M, Teoh H, Verma S (2010) Adropin is a novel regulator of endothelial function. Circulation 122:185–192CrossRef
6.
go back to reference Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, Sahin I, Kocaman N, Citil C, Kendir Y (2013) Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 380:73–81CrossRefPubMed Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, Sahin I, Kocaman N, Citil C, Kendir Y (2013) Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem 380:73–81CrossRefPubMed
7.
go back to reference van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755CrossRefPubMed van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755CrossRefPubMed
8.
go back to reference International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
9.
go back to reference Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–598CrossRefPubMedPubMedCentral Valentini G, Della Rossa A, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60:592–598CrossRefPubMedPubMedCentral
10.
go back to reference Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed Medsger TA Jr, Silman AJ, Steen VD et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159–2167PubMed
11.
go back to reference Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281–1285PubMed Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281–1285PubMed
12.
go back to reference Isik A, Koca SS, Ustundag B, Selek S (2007) Decreased total antioxidant response and increased oxidative stress in Behcet’s disease. Tohoku J Exp Med 212:133–141CrossRefPubMed Isik A, Koca SS, Ustundag B, Selek S (2007) Decreased total antioxidant response and increased oxidative stress in Behcet’s disease. Tohoku J Exp Med 212:133–141CrossRefPubMed
13.
go back to reference Yilmaz S, Simsek I, Cinar M, Erdem H, Kose O, Yazici Y, Pay S (2013) Patient-driven assessment of disease activity in Behçet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet’s syndrome activity score. Clin Exp Rheumatol 31:77–83PubMed Yilmaz S, Simsek I, Cinar M, Erdem H, Kose O, Yazici Y, Pay S (2013) Patient-driven assessment of disease activity in Behçet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet’s syndrome activity score. Clin Exp Rheumatol 31:77–83PubMed
14.
go back to reference Wei J, Zhu H, Komura K et al (2014) A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Ann Rheum Dis 73:446–454CrossRefPubMedPubMedCentral Wei J, Zhu H, Komura K et al (2014) A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Ann Rheum Dis 73:446–454CrossRefPubMedPubMedCentral
15.
go back to reference Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, Babacan T, Tarakcioglu M (2012) Serum leptin, resistin and TNF-a levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15:374–379CrossRefPubMed Pehlivan Y, Onat AM, Ceylan N, Turkbeyler IH, Buyukhatipoglu H, Comez G, Babacan T, Tarakcioglu M (2012) Serum leptin, resistin and TNF-a levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis 15:374–379CrossRefPubMed
16.
go back to reference Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML, Sodin-Semrl S, Varga J (2012) Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker. Arthritis Res Ther 14:R102CrossRefPubMedPubMedCentral Lakota K, Wei J, Carns M, Hinchcliff M, Lee J, Whitfield ML, Sodin-Semrl S, Varga J (2012) Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker. Arthritis Res Ther 14:R102CrossRefPubMedPubMedCentral
17.
go back to reference Lian W, Gu X, Qin Y, Zheng X (2011) Elevated plasma levels of adropin in heart failure patients. Intern Med 50:1523–1527CrossRefPubMed Lian W, Gu X, Qin Y, Zheng X (2011) Elevated plasma levels of adropin in heart failure patients. Intern Med 50:1523–1527CrossRefPubMed
18.
go back to reference Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, Altas Y, Aydin S, Aydin S (2013) Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 31:174–178CrossRefPubMed Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, Altas Y, Aydin S, Aydin S (2013) Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 31:174–178CrossRefPubMed
19.
go back to reference Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S (2013) Mellitus plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes. J Investig Med 61:1161–1164CrossRefPubMed Topuz M, Celik A, Aslantas T, Demir AK, Aydin S, Aydin S (2013) Mellitus plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes. J Investig Med 61:1161–1164CrossRefPubMed
20.
go back to reference Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H, Tan HL, Bandla HP (2013) Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. J Pediatr 163:1122–1126CrossRefPubMedPubMedCentral Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H, Tan HL, Bandla HP (2013) Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. J Pediatr 163:1122–1126CrossRefPubMedPubMedCentral
21.
go back to reference Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, Culler MD, Mynatt RL, Butler AA (2012) Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity 20:1394–1402CrossRefPubMed Ganesh Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, Culler MD, Mynatt RL, Butler AA (2012) Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity 20:1394–1402CrossRefPubMed
22.
go back to reference Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRefPubMed Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRefPubMed
23.
go back to reference Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543CrossRefPubMed Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F (1995) Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540–543CrossRefPubMed
24.
go back to reference Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543–546CrossRefPubMed Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543–546CrossRefPubMed
25.
go back to reference Evereklioglu C, Inalöz HS, Kirtak N, Doganay S, Bülbül M, Ozerol E, Er H, Ozbek E (2002) Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 147:331–336CrossRefPubMed Evereklioglu C, Inalöz HS, Kirtak N, Doganay S, Bülbül M, Ozerol E, Er H, Ozbek E (2002) Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity. Br J Dermatol 147:331–336CrossRefPubMed
26.
go back to reference Marighela TF, Genaro Pde S, Pinheiro MM, Szejnfeld VL, Kayser C (2013) Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol 32:1037–1044CrossRefPubMed Marighela TF, Genaro Pde S, Pinheiro MM, Szejnfeld VL, Kayser C (2013) Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol 32:1037–1044CrossRefPubMed
27.
go back to reference Baron M, Hudson M, Steele R, Canadian Scleroderma Research Group (2009) Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma Research Group database. J Rheumatol 36:2737–2743CrossRefPubMed Baron M, Hudson M, Steele R, Canadian Scleroderma Research Group (2009) Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma Research Group database. J Rheumatol 36:2737–2743CrossRefPubMed
28.
go back to reference Kuhla A, Hahn S, Butschkau A, Lange S, Wree A, Vollmar B (2014) Lifelong caloric restriction reprograms hepatic fat metabolism in mice. J Gerontol A Biol Sci Med Sci 69:915–922CrossRefPubMed Kuhla A, Hahn S, Butschkau A, Lange S, Wree A, Vollmar B (2014) Lifelong caloric restriction reprograms hepatic fat metabolism in mice. J Gerontol A Biol Sci Med Sci 69:915–922CrossRefPubMed
29.
go back to reference Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48:iii3–iii7CrossRefPubMed Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology 48:iii3–iii7CrossRefPubMed
30.
go back to reference Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (2011) Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 10:590–594CrossRefPubMed Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (2011) Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 10:590–594CrossRefPubMed
Metadata
Title
Serum adropin level and ENHO gene expression in systemic sclerosis
Authors
Servet Yolbas
Murat Kara
Musa Yilmaz
Suleyman Aydin
Suleyman Serdar Koca
Publication date
01-06-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 6/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3266-1

Other articles of this Issue 6/2016

Clinical Rheumatology 6/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine